Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

Status:
Active, not recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Prospective national multicenter open label phase II Remodel WM3 trial

Phase 2

French Innovative Leukemia Organisation

Idelalisib
Obinutuzumab